Case report: (18)F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient

BACKGROUND: Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) has become the commonest first-line treatment of hormonal receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC). However, therapy is quite individualized after progression of dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Bo, Hao, Zhixin, Xu, Ying, Wang, Zhe, Yao, Ru, Wang, Xuefei, Ren, Chao, Zhou, Yidong, Sun, Qiang, Huo, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816999/
https://www.ncbi.nlm.nih.gov/pubmed/36620595
http://dx.doi.org/10.3389/fonc.2022.1095779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816999/
https://www.ncbi.nlm.nih.gov/pubmed/36620595
http://dx.doi.org/10.3389/fonc.2022.1095779

Ejemplares similares